Equities
  • Price (EUR)3.92
  • Today's Change0.193 / 5.17%
  • Shares traded1.00k
  • 1 Year change-64.00%
  • Beta1.3933
Data delayed at least 15 minutes, as of Nov 18 2019 16:16 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

  • Revenue in USD (TTM)2.94bn
  • Net income in USD-411.91m
  • Incorporated2013
  • Employees2.91k
  • Location
    Endo International PLCMinerva House, Simmonscourt RoadDUBLIN 000 00IrelandIRL
  • Phone+353 12682000
  • Websitehttp://www.endo.com
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.